Immuneering Corporation

NasdaqGM:IMRX Stock Report

Market Cap: US$71.2m

Immuneering Future Growth

Future criteria checks 0/6

Immuneering's earnings are forecast to decline at 16.3% per annum while its annual revenue is expected to grow at 67.4% per year. EPS is expected to grow by 0.5% per annum. Return on equity is forecast to be -108.3% in 3 years.

Key information

-16.3%

Earnings growth rate

0.5%

EPS growth rate

Biotechs earnings growth20.6%
Revenue growth rate67.4%
Future return on equity-108.3%
Analyst coverage

Good

Last updated15 Mar 2024

Recent future growth updates

Recent updates

Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone

Mar 19

Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?

Jan 06
Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?

We're Not Very Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Rate

Aug 17
We're Not Very Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Rate

Immuneering wins FDA nod to study lead asset in solid tumors

Sep 30

Immuneering seeks FDA nod to conduct clinical trial for lead cancer candidate

Sep 02

Immuneering initiated a Buy by Chardan, PT set to $18

Jul 08

Earnings and Revenue Growth Forecasts

NasdaqGM:IMRX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026N/A-114N/A-1524
12/31/2025N/A-95N/A-1255
12/31/2024N/A-73N/A-778
12/31/2023N/A-53-49-49N/A
9/30/20230-52-49-49N/A
6/30/20230-52-48-48N/A
3/31/20230-51-47-46N/A
12/31/20220-51-45-44N/A
9/30/20221-48-42-42N/A
6/30/20221-44-40-40N/A
3/31/20222-40-37-37N/A
12/31/20212-34-31-31N/A
9/30/20213-29-27-27N/A
6/30/20213-24-22-22N/A
3/31/20213-20-19-18N/A
12/31/20202-17-15-15N/A
12/31/20192-8-4-4N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IMRX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IMRX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IMRX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IMRX is forecast to have no revenue next year.

High Growth Revenue: IMRX is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: IMRX is forecast to be unprofitable in 3 years.


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.